Updated October 25, 2026 · Sources linked below
A small cut healing and a damaged joint recovering are both biological processes, but they are not the same process. Different tissues have different capacities to repair, and “cellular regeneration” is too broad a phrase to predict what a treatment will accomplish.
Repair can take more than one form
Recovery may involve inflammation resolving, tissue remodeling, compensation by surrounding structures, or changes in how a person moves. Improvement does not necessarily mean that a tissue has returned to its original structure.
Osteoarthritis provides an example: it involves the whole joint, including cartilage and surrounding tissues. Treatment can improve symptoms and function without demonstrating that lost cartilage has been rebuilt. [1]
A treatment claim needs a defined endpoint
If an advertisement promises repair, ask what evidence would demonstrate it. Pain scores, walking ability, imaging findings, and laboratory markers answer different questions. A study should explain which outcome it measured and how that relates to the claim.
Research on living cells or cell-derived products cannot be generalized to any injection called regenerative. FDA approval is specific to a product and indication, as illustrated by Ryoncil’s pediatric graft-versus-host disease approval. [2] FDA also warns about unapproved regenerative-medicine products marketed for broad uses. [3]
Put recovery goals into everyday terms
For someone with a musculoskeletal problem, useful goals might include walking farther, returning to an activity, or needing less assistance. These outcomes can guide rehabilitation and follow-up while research into repair continues.
Questions to clarify a claim
- What tissue is expected to change, and how would that be measured?
- Is the proposed benefit pain relief, improved function, structural repair, or all three?
- Was that result shown in controlled human studies?
- What established treatment and rehabilitation options remain available?
Precise language makes treatment choices easier to assess. A broad promise of regeneration is less useful than a clear explanation of the expected benefit, uncertainty, and risk.
For a practical comparison of the terminology and questions to bring to an appointment, see our guide to exosomes, stem cells and PRP. Meet Dan McCarthy, PA, and the OlympusMD team, or call (470) 359-4815 with questions about clinic services.
Sources and further reading
- NIAMS: osteoarthritis symptoms, causes and treatment
- FDA: Ryoncil approval for pediatric steroid-refractory acute graft-versus-host disease, December 18, 2024
- FDA: patient information about regenerative medicine therapies
Patient education from OlympusMD Wellness in Milton, Georgia. This article provides general information and does not replace an individual medical evaluation.
